MYGN
MYRIAD GENETICS INC
Next earnings Aug 3, 2026 (after close) · consensus $-0.06 EPS, $210M rev
Last earnings +1.8% on 2026-05-05
$5.99
▲ +2.39%$5.99▲ +14.10%
over 1Y
L $3.55H $8.18
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.4%
1W+10.3%
1M+39.0%
3M+26.1%
YTD-2.4%
1Y+14.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Hold
Molecular-diagnostics leader with flat revenue, deepening losses, thin cash and new debt covenants — cheap for a reason, not investable now.
Revenue $825M · FY2025
Myriad is a real franchise — a hereditary-cancer pioneer with ~70% gross margins ($577M gross profit on $825M revenue) and genuine reach in community oncology, prenatal and mental health. But the income statement is the story: revenue actually shrank 1.6% in FY2025 to $825M (down from $838M in FY2024), while the company posted a -$387M operating loss and a -$366M net loss — a -47% operating margin and a -99% return on equity. Losses have been chronic and are worsening, not converging: net income has been negative every year shown (FY2021 -$27M → FY2022 -$112M → FY2023 -$263M → FY2024 -$127M → FY2025 -$366M), and accumulated deficit now sits at -$1.12B. This is not a young company on a path to scale profits; it is a mature-revenue business that cannot convert 70% gross margin into a profit.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 12:17 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $691M | $678M | $753M | $838M | $825M |
| Gross profit | — | $476M | $517M | $585M | $577M |
| Operating income | -$191M | -$141M | -$257M | -$124M | -$387M |
| Net income | -$27.2M | -$112M | -$263M | -$127M | -$366M |
| Diluted EPS | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 |
| Net margin | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$536M
EV / EBITDA—
EV / Sales0.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-64.7%
FCF yield-7.7%
Quality & risk
ROIC (est.)-62.7%
Free cash flow-$43.5M
Total debt$120M
Net cash$29.7M
Altman Z-Score-1.53 distress
Piotroski F-Score5/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Officer / director change2026-06-23
Executive/officer change (Item 5.02) disclosed amid ongoing turnaround
- 8-K Officer / director change2026-06-04
Annual meeting: directors elected, votes certified (5.07); routine governance
- 10-Q Quarterly report2026-05-06
Q1 2026: continued operating losses; liquidity and debt covenants in focus
- 8-K Earnings results2026-05-05
Q1 2026 results released; losses persist as revenue stays roughly flat
- DEF 14A Proxy statement2026-04-14
2026 proxy: board slate and exec comp for vote; routine governance
- S-3 Shelf registration (potential raise)2026-02-24
FY2025 10-K: -$366M loss, $150M cash, debt-covenant and funding risks flagged
- 10-K Annual report2026-02-24
FY2025 10-K: -$366M loss, $150M cash, debt-covenant and funding risks flagged
- 8-K Earnings results2026-02-23
FY2025 results: revenue -1.6% and net loss widened to -$366M
- 8-K Earnings results2026-01-12
Preliminary 2025 results / 2026 outlook (JPM conference)
Recent filings
all on EDGAR ↗4Period ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-172026-06-23open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-082026-06-09open ↗144Filing2026-06-08open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗
Frequently asked
- Is MYRIAD GENETICS INC (MYGN) a buy?
- MYGN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Molecular-diagnostics leader with flat revenue, deepening losses, thin cash and new debt covenants — cheap for a reason, not investable now.
- What is MYRIAD GENETICS INC's quality score?
- MYGN scores 50.34245168078862/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000899923, latest 10-Q filed 2026-05-06) · EODHD · Proprietary analysis · as of 7/3/2026, 4:17:38 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.